应用天然产物 ›› 2025, Vol. 15 ›› Issue (5): 50-50.DOI: 10.1007/s13659-025-00535-6
Bei Xiong1, Jin-Jian Lu1,2,3, Hongwei Guo4, Mingqing Huang5, Ting Li1,2
收稿日期:2025-06-04
发布日期:2025-11-06
通讯作者:
Jin-Jian Lu,E-mail:jinjianlu@um.edu.mo;Mingqing Huang,E-mail:hmq1115@126.com;Ting Li,E-mail:tingli@um.edu.mo
基金资助:Bei Xiong1, Jin-Jian Lu1,2,3, Hongwei Guo4, Mingqing Huang5, Ting Li1,2
Received:2025-06-04
Published:2025-11-06
Contact:
Jin-Jian Lu,E-mail:jinjianlu@um.edu.mo;Mingqing Huang,E-mail:hmq1115@126.com;Ting Li,E-mail:tingli@um.edu.mo
Supported by:摘要： The extraction of anticancer agents from medicinal plants represents a highly promising research frontier. Ginkgetin, a natural biflavone, is one of the effective pharmacological components of Ginkgo biloba leaves (GBLs). This natural product exhibits significant anti-cancer efficacy against a variety of cancer cells in vitro and demonstrates a potent inhibitory impact on tumor growth in vivo without severe toxicity. Additionally, ginkgetin synergizes with chemotherapy drugs or adjuvant therapies to potentiate antitumor effects and reduce side effects. These compelling findings underscore Ginkgetin's potential as a promising candidate for novel anti-cancer therapeutics. Therefore, this review systematically summarizes the remarkable anticancer effects of ginkgetin and elucidates its multifaceted anticancer mechanisms, including inducing cell cycle arrest, triggering programmed cell death, and preventing invasion and angiogenesis. From a molecular mechanism perspective, ginkgetin exerts anti-cancer activity by modulating critical signaling pathways (e.g. JAK/STAT, Wnt/β-catenin, AKT/GSK-3β, MAPKs, and estrogen receptor pathways) and regulating microRNA expression levels. Furthermore, target identification, research limitations, future directions, and application prospects are comprehensively outlined, aiming to facilitate the clinical translation of ginkgetin.
Bei Xiong, Jin-Jian Lu, Hongwei Guo, Mingqing Huang, Ting Li. Ginkgetin from Ginkgo biloba: mechanistic insights into anticancer efficacy[J]. 应用天然产物, 2025, 15(5): 50-50.
Bei Xiong, Jin-Jian Lu, Hongwei Guo, Mingqing Huang, Ting Li. Ginkgetin from Ginkgo biloba: mechanistic insights into anticancer efficacy[J]. Natural Products and Bioprospecting, 2025, 15(5): 50-50.
| [1] Zhao YP, et al. Resequencing 545 ginkgo genomes across the world reveals the evolutionary history of the living fossil. Nat Commun. 2019;10(1):4201. [2] McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med. 2001;7(5):70-86. [3] Chen Y, et al. Ginkgo biloba. Trends Genet. 2021;37(5):488-9. [4] Boateng ID. Ginkgols and bilobols in Ginkgo biloba L. a review of their extraction and bioactivities. Phytother Res. 2023;37(8):3211-23. [5] Guo J, et al. Overview and recent progress on the biosynthesis and regulation of flavonoids in Ginkgo biloba L. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms241914604. [6] Mohammadi Zonouz A, Ghasemzadeh Rahbardar M, Hosseinzadeh H. The molecular mechanisms of ginkgo (Ginkgo biloba) activity in signaling pathways: a comprehensive review. Phytomedicine. 2024;126: 155352. [7] Shareena G, Kumar D. Traversing through half a century research timeline on Ginkgo biloba, in transforming a botanical rarity into an active functional food ingredient. Biomed Pharmacother. 2022;153: 113299. [8] Omidkhoda SF, Razavi BM, Hosseinzadeh H. Protective effects of Ginkgo biloba L. against natural toxins, chemical toxicities, and radiation: a comprehensive review. Phytother Res. 2019;33(11):2821-40. [9] Boateng ID. A critical review of current technologies used to reduce ginkgotoxin, ginkgotoxin-5’-glucoside, ginkgolic acid, allergic glycoprotein, and cyanide in Ginkgo biloba L. seed. Food Chem. 2022;382: 132408. [10] Trabert M, Seifert R. Critical analysis of ginkgo preparations: comparison of approved drugs and dietary supplements marketed in Germany. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(1):451-61. [11] Su X, et al. Medicinal values and potential risks evaluation of Ginkgo biloba leaf extract (GBE) drinks made from the leaves in autumn as dietary supplements. Molecules. 2022. https://doi.org/10.3390/molecules27217479. [12] Yuan C, et al. Efficacy and safety of Ginkgo biloba extract as an adjuvant in the treatment of Chinese patients with sudden hearing loss: a meta-analysis. Pharm Biol. 2023;61(1):610-20. [13] Asiwe JN, et al. Ginkgo biloba supplement modulates mTOR/ERK1/2 activities to mediate cardio-protection in cyclosporin-A-induced cardiotoxicity in Wistar rats. Clin Tradit Med Pharmacol. 2024;5(1): 200134. [14] Yu J, et al. New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer. Phytomedicine. 2024;122: 155088. [15] Lu J, et al. Hyperspectral imaging combined with deep transfer learning to evaluate flavonoids content in Ginkgo biloba leaves. Int J Mol Sci. 2024. https://doi.org/10.3390/ijms25179584. [16] Mao D, et al. Function, biosynthesis, and regulation mechanisms of flavonoids in Ginkgo biloba. Fruit Res. 2023. https://doi.org/10.48130/FruRes-2023-0018. [17] Li X, et al. 3’,8″-dimerization enhances the antioxidant capacity of flavonoids: evidence from acacetin and isoginkgetin. Molecules. 2019. https://doi.org/10.3390/molecules24112039. [18] Kovač Tomas M, Jurčević I, Šamec D. Tissue-specific profiling of biflavonoids in Ginkgo (Ginkgo biloba L.). Plants. 2022. https://doi.org/10.3390/plants12010147. [19] Sagrera G, et al. Synthesis and antifungal activities of natural and synthetic biflavonoids. Bioorg Med Chem. 2011;19(10):3060-73. [20] Tao Z, et al. Therapeutic effect of ginkgetin on smoke-induced airway inflammation by down-regulating the c/EBPβ signaling pathway and CCL2 expression. J Ethnopharmacol. 2024;331: 118284. [21] Hu B, et al. Ginkgetin alleviates intervertebral disc degeneration by inhibiting apoptosis, inflammation, and disturbance of extracellular matrix synthesis and catabolism via inactivation of NLRP3 inflammasome. Immunol Invest. 2023;52(5):546-60. [22] Li G, et al. Ginkgetin in vitro and in vivo reduces Streptococcus suis virulence by inhibiting suilysin activity. J Appl Microbiol. 2019;127(5):1556-63. [23] Menezes J, Campos VR. Natural biflavonoids as potential therapeutic agents against microbial diseases. Sci Total Environ. 2021;769: 145168. [24] Castañeda P, et al. Effects of some compounds isolated fromCelaenodendron mexicanum standl (euphorbiaceae) on seeds and phytopathogenic fungi. J Chem Ecol. 1992;18(7):1025-37. [25] Jurčević Šangut I, et al. A comparative analysis of radical scavenging, antifungal and enzyme inhibition activity of 3’-8″-biflavones and their monomeric subunits. Antioxidants. 2023. https://doi.org/10.3390/antiox12101854. [26] Patel CN, et al. Computational investigation of natural compounds as potential main protease [M(pro)] inhibitors for SARS-CoV-2 virus. Comput Biol Med. 2022;151(Pt A): 106318. [27] Sharma S, et al. Avocado-derived extracellular vesicles loaded with ginkgetin and berberine prevent inflammation and macrophage foam cell formation. J Cell Mol Med. 2024;28(7): e18177. [28] Wang LT, et al. Biflavonoids from Ginkgo biloba leaves as a novel anti-atherosclerotic candidate: inhibition potency and mechanistic analysis. Phytomedicine. 2022;102: 154053. [29] Cho YL, et al. Ginkgetin, a biflavone from Ginkgo biloba leaves, prevents adipogenesis through STAT5-mediated PPARγ and C/EBPα regulation. Pharmacol Res. 2019;139:325-36. [30] Akbar A, Ijaz MU. Pharmacotherapeutic potential of ginkgetin against polystyrene microplastics-instigated testicular toxicity in rats: a biochemical, spermatological, and histopathological assessment. Environ Sci Pollut Res Int. 2024;31(6):9031-44. [31] Yamaguchi LF, et al. Biflavonoids from Brazilian pine Araucaria angustifolia as potentials protective agents against DNA damage and lipoperoxidation. Phytochemistry. 2005;66(18):2238-47. [32] Liu Y, et al. Ginkgetin alleviates inflammation and senescence by targeting STING. Adv Sci (Weinh). 2024. https://doi.org/10.1002/advs.202407222. [33] Smer-Barreto V, et al. Discovery of senolytics using machine learning. Nat Commun. 2023;14(1):3445. [34] Ren G, et al. Modulation of Bleomycin-induced oxidative stress and pulmonary fibrosis by Ginkgetin in mice via AMPK. Curr Mol Pharmacol. 2023;16(2):217-27. [35] Wang C, et al. Ginkgetin exhibits antifibrotic effects by inducing hepatic stellate cell apoptosis via STAT1 activation. Phytother Res. 2024;38(3):1367-80. [36] Tatlı Çankaya I, et al. Neuroprotective potential of biflavone Ginkgetin: a review. Life. 2023. https://doi.org/10.3390/life13020562. [37] Tian Z, Tang C, Wang Z. Neuroprotective effect of ginkgetin in experimental cerebral ischemia/reperfusion via apoptosis inhibition and PI3K/Akt/mTOR signaling pathway activation. J Cell Biochem. 2019;120(10):18487-95. [38] Jeon YJ, et al. Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity. Cancer Sci. 2015;106(4):413-20. [39] Sun CM, et al. Selective cytotoxicity of ginkgetin from Selaginella moellendorffii. J Nat Prod. 1997;60(4):382-4. [40] Adnan M, et al. Ginkgetin: a natural biflavone with versatile pharmacological activities. Food Chem Toxicol. 2020;145: 111642. [41] Park Y, et al. Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor. Oncol Lett. 2017;14(4):5027-33. [42] Cao J, et al. Ginkgetin inhibits growth of breast carcinoma via regulating MAPKs pathway. Biomed Pharmacother. 2017;96:450-8. [43] Duan Q, et al. Ginkgetin enhances breast cancer radiotherapy sensitization by suppressing NRF2-HO-1 axis activity. Toxicol Appl Pharmacol. 2025;495: 117199. [44] Alu A, et al. Ginkgo biloba derivative ginkgetin inhibits breast cancer growth by regulating the miRNA-122-5p/GALNT10 axis. Chin Med J (Engl). 2024;137(19):2387-9. [45] Su Y, et al. Studies on the cytotoxic mechanisms of ginkgetin in a human ovarian adenocarcinoma cell line. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(1):82-90. [46] Cheng J, Li Y, Kong J. Ginkgetin inhibits proliferation of HeLa cells via activation of p38/NF-κB pathway. Cell Mol Biol (Noisy-le-grand). 2019;65(4):79-82. [47] Lee YJ, et al. Ginkgetin induces G2-phase arrest in HCT116 colon cancer cells through the modulation of b-Myb and miRNA34a expression. Int J Oncol. 2017;51(4):1331-42. [48] Zhang S, et al. Ginkgo biflavones cause p53 wild-type dependent cell death in a transcription-independent manner of p53. J Nat Prod. 2023;86(2):346-56. [49] Liu Q, et al. Anti-tumor effect of ginkgetin on human hepatocellular carcinoma cell lines by inducing cell cycle arrest and promoting cell apoptosis. Cell Cycle. 2022;21(1):74-85. [50] Ren Y, et al. Ginkgetin induces apoptosis in 786-O cell line via suppression of JAK2-STAT3 pathway. Iran J Basic Med Sci. 2016;19(11):1245-50. [51] Pan LL, et al. Corrigendum to: Ginkgetin inhibits proliferation of human leukemia cells via the TNF-α signaling pathway. Z Naturforsch C J Biosci. 2017;72(11-12):507. [52] Baek SH, et al. Ginkgetin blocks constitutive STAT3 activation and induces apoptosis through induction of SHP-1 and PTEN tyrosine phosphatases. Phytother Res. 2016;30(4):567-76. [53] Liu K, et al. Integrating network pharmacology prediction and experimental investigation to verify ginkgetin anti-invasion and metastasis of human lung adenocarcinoma cells via the Akt/GSK-3β/Snail and Wnt/β-catenin pathway. Front Pharmacol. 2023;14:1135601. [54] Lou JS, et al. Ginkgetin induces autophagic cell death through p62/SQSTM1-mediated autolysosome formation and redox setting in non-small cell lung cancer. Oncotarget. 2017;8(54):93131-48. [55] Sun L, et al. Ginkgetin inhibits the proliferation and migration of lung cancer cells via FAK/STAT3/AKT pathway. Mol Biol Rep. 2025;52(1):458. [56] Ye ZN, et al. Biflavone Ginkgetin, a novel Wnt inhibitor, suppresses the growth of medulloblastoma. Nat Prod Bioprospect. 2015;5(2):91-7. [57] Liu L, et al. Structure-based discovery of Licoflavone B and Ginkgetin targeting c-Myc G-quadruplex to suppress c-Myc transcription and myeloma growth. Chem Biol Drug Des. 2022;100(4):525-33. [58] Xiong M, et al. Ginkgetin exerts growth inhibitory and apoptotic effects on osteosarcoma cells through inhibition of STAT3 and activation of caspase-3/9. Oncol Rep. 2016;35(2):1034-40. [59] Wu L, et al. Ginkgetin suppresses ovarian cancer growth through inhibition of JAK2/STAT3 and MAPKs signaling pathways. Phytomedicine. 2023;116: 154846. [60] You OH, et al. Ginkgetin induces apoptosis via activation of caspase and inhibition of survival genes in PC-3 prostate cancer cells. Bioorg Med Chem Lett. 2013;23(9):2692-5. [61] Lou JS, et al. Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine. 2021;80: 153370. [62] Hu WH, et al. Synergy of Ginkgetin and resveratrol in suppressing VEGF-induced angiogenesis: a therapy in treating colorectal cancer. Cancers (Basel). 2019. https://doi.org/10.3390/cancers11121828. [63] Patra D, et al. Anti-cancer drug molecules targeting cancer cell cycle and proliferation. Adv Protein Chem Struct Biol. 2023;135:343-95. [64] Suski JM, et al. Targeting cell-cycle machinery in cancer. Cancer Cell. 2021;39(6):759-78. [65] Ren Y, Kinghorn AD. Development of potential antitumor agents from the scaffolds of plant-derived terpenoid lactones. J Med Chem. 2020;63(24):15410-48. [66] Kim KH, et al. Different apoptotic effects of saxifragifolin C in human breast cancer cells. Arch Pharm Res. 2016;39(4):577-89. [67] Vethakanraj HS, et al. Anticancer effect of acid ceramidase inhibitor ceranib-2 in human breast cancer cell lines MCF-7, MDA MB-231 by the activation of SAPK/JNK, p38 MAPK apoptotic pathways, inhibition of the Akt pathway, downregulation of ERα. Anticancer Drugs. 2018;29(1):50-60. [68] Kim KH, et al. Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells. Phytomedicine. 2015;22(9):820-8. [69] Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023;24(8):560-75. [70] Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19(1):12. [71] Zhang LL, et al. Phanginin R induces cytoprotective autophagy via JNK/c-Jun signaling pathway in non-small cell lung cancer A549 cells. Anticancer Agents Med Chem. 2020;20(8):982-8. [72] Pan J, et al. Ginkgetin attenuates cerebral ischemia-reperfusion induced autophagy and cell death via modulation of the NF-κB/p53 signaling pathway. 2019. Biosci Rep. https://doi.org/10.1042/BSR20191452. [73] Wei L, et al. Ginkgetin alleviates high glucose-evoked mesangial cell oxidative stress injury, inflammation, and extracellular matrix (ECM) deposition in an AMPK/mTOR-mediated autophagy axis. Chem Biol Drug Des. 2021;98(4):620-30. [74] Liu J, et al. Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives. Mol Cancer. 2024;23(1):22. [75] Yuan R, et al. Natural products to prevent drug resistance in cancer chemotherapy: a review. Ann N Y Acad Sci. 2017;1401(1):19-27. [76] Niu X, et al. Autophagy in cancer development, immune evasion, and drug resistance. Drug Resist Updat. 2025;78: 101170. [77] Poillet-Perez L, Sarry JE, Joffre C. Autophagy is a major metabolic regulator involved in cancer therapy resistance. Cell Rep. 2021;36(7): 109528. [78] Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381-96. [79] Newton K, et al. Cell death. Cell. 2024;187(2):235-56. [80] Mokhtari Tabar MM, et al. Computational discovery of novel GPX4 inhibitors from herbal sources as potential ferroptosis inducers in cancer therapy. Arch Biochem Biophys. 2024;764: 110231. [81] Wang HJ, et al. TFEB promotes Ginkgetin-induced ferroptosis via TRIM25 mediated GPX4 lysosomal degradation in EGFR wide-type lung adenocarcinoma. Theranostics. 2025;15(7):2991-3012. [82] Kang R, Kroemer G, Tang D. The tumor suppressor protein p53 and the ferroptosis network. Free Radic Biol Med. 2019;133:162-8. [83] Liu ZL, et al. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198. [84] Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov. 2023;22(6):476-95. [85] Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8(1):455. [86] de Almeida LGN, et al. Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology. Pharmacol Rev. 2022;74(3):712-68. [87] Fontana R, Mestre-Farrera A, Yang J. Update on epithelial-mesenchymal plasticity in cancer progression. Annu Rev Pathol. 2024;19:133-56. [88] Cordani M, et al. Signaling, cancer cell plasticity, and intratumor heterogeneity. Cell Commun Signal. 2024;22(1):255. [89] Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129. [90] Jiang X, et al. Recent advances in identifying protein targets of bioactive natural products. Heliyon. 2024;10(13): e33917. [91] Bhadresha K, et al. Computational investigation of ginkgetin and theaflavin as potential inhibitors of heat shock protein 90 (Hsp90). J Biomol Struct Dyn. 2022;40(24):13675-81. [92] Kim HP, et al. Biochemical pharmacology of biflavonoids: implications for anti-inflammatory action. Arch Pharm Res. 2008;31(3):265-73. [93] Chen J, et al. Conditional sequential delivery of ginkgetin and rapamycin orchestrates inflammation and autophagy to alleviate intervertebral disc degeneration. J Control Release. 2025;381: 113556. [94] Xiong X, et al. Insights into Amentoflavone: a natural multifunctional biflavonoid. Front Pharmacol. 2021;12: 768708. [95] Feng Y, et al. Preparation of amentoflavone-loaded DSPE-PEG(2000) micelles with improved bioavailability and in vitro antitumor efficacy. Biomed Chromatogr. 2023;37(9): e5690. [96] Wang B, et al. Potent inhibition of human cytochrome P450 3A4 by biflavone components from Ginkgo biloba and Selaginella tamariscina. Front Pharmacol. 2022;13: 856784. [97] Li YY, et al. Potential hepatic and renal toxicity induced by the biflavonoids from Ginkgo biloba. Chin J Nat Med. 2019;17(9):672-81. [98] Pang HL, et al. Discovery and characterization of the key constituents in Ginkgo biloba leaf extract with potent inhibitory effects on human UDP-glucuronosyltransferase 1A1. Front Pharmacol. 2022;13: 815235. [99] Feng R, et al. Toxicity studies of compound spermatogenic pill: acute toxicity and subacute toxicity. J Ethnopharmacol. 2025;337: 118757. [100] Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013;45(6):1121-32. [101] Wendlocha D, et al. Selected flavonols targeting cell death pathways in cancer therapy: the latest achievements in research on apoptosis, autophagy, necroptosis, pyroptosis, ferroptosis, and cuproptosis. Nutrients. 2024. https://doi.org/10.3390/nu16081201. [102] Jung YY, et al. Kaempferide triggers apoptosis and paraptosis in pancreatic tumor cells by modulating the ROS production, SHP-1 expression, and the STAT3 pathway. IUBMB Life. 2024;76(9):745-59. [103] Talib WH, et al. Natural products and altered metabolism in cancer: therapeutic targets and mechanisms of action. Int J Mol Sci. 2024. https://doi.org/10.3390/ijms25179593. [104] Esteller M, et al. The epigenetic hallmarks of cancer. Cancer Discov. 2024;14(10):1783-809. [105] Lee SW, Frankston CM, Kim J. Epigenome editing in cancer: advances and challenges for potential therapeutic options. Int Rev Cell Mol Biol. 2024;383:191-230. [106] Wang L, et al. Advances in targeting tumor microenvironment for immunotherapy. Front Immunol. 2024;15:1472772. [107] Liu Y, et al. Drug resistance and tumor immune microenvironment: an overview of current understandings (Review). Int J Oncol. 2024. https://doi.org/10.3892/ijo.2024.5684. [108] Chhabra Y, Weeraratna AT. Fibroblasts in cancer: unity in heterogeneity. Cell. 2023;186(8):1580-609. [109] Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25(4):198-213. [110] Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221: 107753. [111] Li T, Huang M, Lu J. Cancer statistics and trends in China: the potential of natural product application. Chin J Nat Med. 2024;22(8):673-5. [112] Wang C, et al. Beneficial effects of ginkgetin on improving nonalcoholic steatohepatitis characterized by bulk and single-cell RNA sequencing analysis. Front Pharmacol. 2023;14:1267445. [113] Wang D, et al. Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer. Gastroenterology. 2021;161(6):1813-29. [114] Lacher SB, et al. PGE(2) limits effector expansion of tumour-infiltrating stem-like CD8(+) T cells. Nature. 2024;629(8011):417-25. [115] Abdolahi S, et al. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022;20(1):206. [116] Chen J, et al. The development and improvement of immunodeficient mice and humanized immune system mouse models. Front Immunol. 2022;13:1007579. [117] Chen X, et al. Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification. Signal Transduct Target Ther. 2020;5(1):72. [118] Ni J, et al. Vanillic acid restores homeostasis of intestinal epithelium in colitis through inhibiting CA9/STIM1-mediated ferroptosis. Pharmacol Res. 2024;202: 107128. [119] Feng F, et al. Label-free target protein characterization for small molecule drugs: recent advances in methods and applications. J Pharm Biomed Anal. 2023;223: 115107. [120] Wang S, et al. Labeled and label-free target identifications of natural products. J Med Chem. 2024;67(20):17980-96. [121] Tan P, et al. Application of omics technologies in studies on antitumor effects of traditional Chinese medicine. Chin Med. 2024;19(1):123. [122] Mullowney MW, et al. Artificial intelligence for natural product drug discovery. Nat Rev Drug Discov. 2023;22(11):895-916. |
| [1] | Delfly Booby Abdjul, Fitri Budiyanto, Joko Tri Wibowo, Tutik Murniasih, Siti Irma Rahmawati, Dwi Wahyu Indriani, Masteria Yunovilsa Putra, Asep Bayu. Unlocking potent anti-tuberculosis natural products through structure–activity relationship analysis[J]. 应用天然产物, 2025, 15(5): 44-44. |
| [2] | Chuan-Su Liu, Bing-Chao Yan, Han-Dong Sun, Jin-Cai Lu, Pema-Tenzin Puno. Bridging chemical space and biological efficacy: advances and challenges in applying generative models in structural modification of natural products[J]. 应用天然产物, 2025, 15(4): 37-37. |
| [3] | Haoqi Dong, Xinni Yang, Peiying Wang, Weiya Huang, Liang Zhang, Song Song, Jiangxin Liu. Identification and verification of methylenetetrahydrofolate dehydrogenase 1-like protein as the binding target of natural product pseudolaric acid A[J]. 应用天然产物, 2025, 15(3): 21-21. |
| [4] | Hesham R. El-Seedi, Mohamed S. Refaey, Nizar Elias, Mohamed F. El-Mallah, Faisal M. K. Albaqami, Ismail Dergaa, Ming Du, Mohamed F. Salem, Haroon Elrasheid Tahir, Maria Dagliaa, Nermeen Yosri, Hongcheng Zhang, Awg H. El-Seedi, Zhiming Guo, Shaden A. M. Khalifa. Marine natural products as a source of novel anticancer drugs: an updated review (2019-2023)[J]. 应用天然产物, 2025, 15(2): 13-13. |
| [5] | Xiaoxia Gu, Xiaotian Zhang, Xueke Zhang, Xinyu Wang, Weiguang Sun, Yonghui Zhang, Zhengxi Hu. Unveiling the mechanism of action of a novel natural dual inhibitor of SARS-CoV-2 Mpro and PLpro with molecular dynamics simulations[J]. 应用天然产物, 2025, 15(1): 3-3. |
| [6] | María I. Osella, Mario O. Salazar, Carlos M. Solís, Ricardo L. E. Furlan. New semisynthetic α-glucosidase inhibitor from a doubly-chemically engineered extract[J]. 应用天然产物, 2025, 15(1): 4-4. |
| [7] | Ahmed H. Elbanna, Xinhui Kou, Dilip V. Prajapati, Surasree Rakshit, Rebecca A. Butcher. Discovery of a parallel family of euglenatide analogs in Euglena gracilis[J]. 应用天然产物, 2025, 15(1): 10-10. |
| [8] | Yanxiao Jia, Dezhi Yang, Wenwen Wang, Kun Hu, Min Yan, Li Zhang, Li Gao, Yang Lu. Recent advances in pharmaceutical cocrystals of theophylline[J]. 应用天然产物, 2024, 14(6): 53-53. |
| [9] | Song-Yu Hou, Bing-Chao Yan, Han-Dong Sun, Pema-Tenzin Puno. Recent advances in the application of [2+2] cycloaddition in the chemical synthesis of cyclobutane-containing natural products[J]. 应用天然产物, 2024, 14(5): 37-37. |
| [10] | Felaine Anne Sumang, Alan Ward, Jeff Errington, Yousef Dashti. Hibiscus acid and hydroxycitric acid dimethyl esters from Hibiscus flowers induce production of dithiolopyrrolone antibiotics by Streptomyces Strain MBN2-2[J]. 应用天然产物, 2024, 14(5): 40-40. |
| [11] | Yifei Xie, Guotong Sun, Yue Tao, Wen Zhang, Shiying Yang, Li Zhang, Yang Lu, Guanhua Du. Current advances on the therapeutic potential of scutellarin: an updated review[J]. 应用天然产物, 2024, 14(3): 20-20. |
| [12] | Chunsong Hu. Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease[J]. 应用天然产物, 2024, 14(2): 2-2. |
| [13] | Shohreh Ariaeenejad, Javad Gharechahi, Mehdi Foroozandeh Shahraki, Fereshteh Fallah Atanaki, Jian-Lin Han, Xue-Zhi Ding, Falk Hildebrand, Mohammad Bahram, Kaveh Kavousi, Ghasem Hosseini Salekdeh. Precision enzyme discovery through targeted mining of metagenomic data[J]. 应用天然产物, 2024, 14(1): 7-7. |
| [14] | Shihui Qin, Yanlang Li, Huiyan Shao, Yang Yu, Yina Yang, Yi Zeng, Jia Huang, Jiang-miao Hu, Liu Yang. Interaction mechanism between luteoloside and corn silk glycans and the synergistic role in hypoglycemic activity[J]. 应用天然产物, 2024, 14(1): 10-10. |
| [15] | Daniel W. Armstrong, Alain Berthod. Occurrence of D-amino acids in natural products[J]. 应用天然产物, 2023, 13(6): 47-47. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
